Page 2 - Dr Stephanie Seneff - Reviewing Some Possible Unintended Consequences of the mRNA Vaccines Against COVID - 19

2021). The sense of urgency around combatting the virus led to the creation, in March 2020, of
Operation Warp Speed (OWS), then-President Donald Trump’s program to bring a vaccine against
COVID-19 to market as quickly as possible (Jacobs and Armstrong, 2020).

OWS established a few more unprecedented aspects of COVID-19. First, it brought the US
Department of Defense into direct collaboration with US health departments with respect to
vaccine distribution (Bonsell, 2021). Second, the National Institutes of Health (NIH) collaborated
with the biotechnology company Moderna in bringing an unprecedented type of vaccine against
infectious disease to market, one utilizing a technology based on messenger RNA (mRNA)
(National Institutes of Health, 2020).
The confluence of these unprecedented events has rapidly brought to public awareness the promise
and potential of mRNA vaccines as a new weapon against infectious diseases into the future. At the
same time, events without precedent are, by definition, without a history and context against which
to fully assess risks, hoped-for benefits, safety, and long-term viability as a positive contribution to
public health.

In this paper we will be briefly reviewing one Unprecedented
particular aspect of these unprecedented events, Many aspects of Covid-19 and subsequent
namely the development and deployment of vaccine development are unprecedented for a
mRNA vaccines against the targeted class of vaccine deployed for use in the general
infectious diseases under the umbrella of “SARS- population. Some of these includes the
CoV-2.” We believe many of the issues we raise following.
here will be applicable to any future mRNA 1. First to use PEG (polyethylene glycol) in an
vaccine that might be produced against other injection (see text)
infectious agents, or in applications related to 2. First to use mRNA vaccine technology
cancer and genetic diseases, while others seem against an infectious agent
specifically relevant to mRNA vaccines currently 3. First time Moderna has brought any product
to market
being implemented against the subclass of corona 4. First to have public health officials telling
viruses. While the promises of this technology those receiving the vaccination to expect an
have been widely heralded, the objectively adverse reaction
assessed risks and safety concerns have received 5. First to be implemented publicly with
far less detailed attention. It is our intention to nothing more than preliminary efficacy data
review several highly concerning molecular (see text)
aspects of infectious disease-related mRNA 6. First vaccine to make no clear claims about
reducing infections, transmissibility, or
technology, and to correlate these with both deaths
documented and potential pathological effects. 7. First coronavirus vaccine ever attempted in
humans
8. First injection of genetically modified
Vaccine Development polynucleotides in the general population
Development of mRNA vaccines against
infectious disease is unprecedented in many ways.
In a 2018 publication sponsored by the Bill and
Melinda Gates Foundation, vaccines were divided into three categories: Simple, Complex, and
Unprecedented (Young et al., 2018). Simple and Complex vaccines represented standard and
modified applications of existing vaccine technologies. Unprecedented represents a category of
International Journal of Vaccine Theory, Practice, and Research 2(1), May 10, 2021 Page | 390